UNSPSC 51132206: Acetaminophen/aspirin/caffeine/calcium gluconate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132206 Acetaminophen/aspirin/caffeine/calcium gluconate is a Commodity code, but recent state and local solicitations tagged under it diverge sharply from the code's nominal scope — they are purchasing naloxone, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products at scale, not the specific analgesic combination the code name describes. State and local health agencies, including county health departments and state HHS commissions, are the primary issuing bodies. The actual work consists of securing bulk pharmaceutical inventories (often through cooperative purchasing alliances), establishing direct contracting relationships between government pharmacy benefit programs and manufacturers, and managing quarterly or ongoing deliveries of critical medical supplies to community health facilities and network locations. Vendors must hold FDA certification, comply with Drug Supply Chain Security Act (DSCSA) requirements, maintain relationships with authorized pharmaceutical wholesalers, and meet rigorous insurance and quality standards.

Recent activity spans Florida, Texas, and Minnesota through multiple issuing mechanisms. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a community health building; the Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded contracts effective July 1, 2026, evaluated 75 percent on price competitiveness and requiring 3 percent administrative fees plus performance penalties of $200–$1,500 per violation. The code shows material recent activity but with minimal alignment to its nominal product name; procurement under this classification appears driven by state and local HHS demand rather than the specific acetaminophen-aspirin-caffeine-calcium gluconate combination.